Table of Content - Macular Degeneration Treatment Market

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study

This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Market Segmentation

By Type
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
By Stage Of Disease
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
By Route Of Administration
- Intravenous Route
- Intravitreal Route
By Sales Channel
- Ambulatory Surgical Centres
- Hospitals
- Other Sales Channels
By Regional Insights
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Bayer AG
- REGENXBIO Inc.
- Aerie Pharmaceutical Inc.
- Panoptica
- Pfizer Inc.
- Hoffmann-La Roche Ltd.
- Regeneron Pharmaceutical Inc.
- Novartis AG
- Bausch Health Companies Inc.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Type
  - Market Snapshot, By Stage of Disease
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Sales Channel
  - Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Increasing burden of retinal disorders worldwide
  - Lack of awareness regarding macular degeneration
  - Increasing demand for safe and effective treatment
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
Macular Degeneration Treatment Market, By Type, 2026-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Dry Age-related Macular Degeneration
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Wet Age-related Macular Degeneration
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
Macular Degeneration Treatment Market, By Stage of Disease, 2026-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Early-stage AMD
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Intermediate AMD
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Late-stage AMD
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
Macular Degeneration Treatment Market, By Route of Administration, 2026-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Intravenous Route
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Intravitreal Route
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
Macular Degeneration Treatment Market, By Sales Channel, 2026-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Ambulatory Surgical Centres
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Hospitals
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Other Sales Channels
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
Macular Degeneration Treatment Market, By Geography, 2026-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  - Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    - U.S.
    - Canada
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  - Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  - Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  - Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Middle East and Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  - Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- REGENXBIO Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Aerie Pharmaceutical Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Panoptica
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Hoffmann-La Roche Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Regeneron Pharmaceutical Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bausch Health Companies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Analyst Views
Section
- Research Methodology
- About us

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE